A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors

[1]  M. Arkin,et al.  SNS-032 is a potent and selective inhibitor of CDK2, 7 and 9 and induces cell death by inhibiting cell cycle progression and the expression of antiapoptotic proteins , 2006 .

[2]  R. Burger,et al.  A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study. , 2005, Gynecologic oncology.

[3]  K. Hunt,et al.  Cyclin E as a prognostic and predictive marker in breast cancer. , 2005, Seminars in Cancer Biology.

[4]  E. Eisenhauer,et al.  Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma , 2004, Investigational New Drugs.

[5]  P. Kantoff,et al.  A Phase II Trial of Flavopiridol (NSC #649890) in Patients with Previously Untreated Metastatic Androgen-Independent Prostate Cancer , 2004, Clinical Cancer Research.

[6]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[7]  M. Kitagawa,et al.  Role of p27Kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer. , 1998, The American journal of pathology.

[8]  D. Santamaría,et al.  Cyclins and CDKS in development and cancer: lessons from genetically modified mice. , 2006, Frontiers in bioscience : a journal and virtual library.

[9]  H. Koeffler,et al.  Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. , 2001, Cancer research.

[10]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.